Clearmind Medicine CEO Addresses Shareholders in 6-K Filing
Ticker: CMND · Form: 6-K · Filed: Apr 9, 2024 · CIK: 1892500
Sentiment: neutral
Topics: 6-K, press-release, shareholder-communication
TL;DR
Clearmind CEO dropped a letter to shareholders, check the 6-K for deets.
AI Summary
Clearmind Medicine Inc. filed a Form 6-K on April 9, 2024, to report a press release from its CEO addressed to shareholders. The press release, titled "Clearmind Medicine CEO Issues Letter to Shareholders," is attached as Exhibit 99.1 to this filing.
Why It Matters
This filing indicates a direct communication from the company's leadership to its investors, potentially providing updates on strategy, performance, or future outlook.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain new financial information or material events.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the 6-K report and subject of the press release.
- April 9, 2024 (date) — Date of the press release and the filing.
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release issued by Clearmind Medicine Inc. on April 9, 2024, titled "Clearmind Medicine CEO Issues Letter to Shareholders."
What is the title of the press release attached to the filing?
The title of the press release attached to the filing is "Clearmind Medicine CEO Issues Letter to Shareholders."
When was the press release issued?
The press release was issued on April 9, 2024.
What is the Commission file number for Clearmind Medicine Inc.?
The Commission file number for Clearmind Medicine Inc. is 001-41557.
What is the standard industrial classification for Clearmind Medicine Inc.?
The standard industrial classification for Clearmind Medicine Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 182 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2024-04-09 16:00:27
Filing Documents
- ea0203555-6k_clearmind.htm (6-K) — 9KB
- ea020355501ex99-1_clearmind.htm (EX-99.1) — 17KB
- 0001213900-24-031582.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: April 9, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 2